Injectable Drug Delivery News

  1. Kindeva And BOL Pharma Using Low Global Warming Potential (GWP) Propellant In Development Of Inhaled Cannabinoid Products 5/11/2022

    Subject to all required regulatory approvals, the products under development are targeted to treat chronic neuropathic pain. If successful, this early-stage activity could lead to the long-term commercial supply of regulated inhaled cannabinoid products using low GWP propellants, leveraging Kindeva’s commercial manufacturing capabilities and BOL’s accumulated know-how and innovation in the field of medical cannabis.

  2. PCI Pharma Services Announces Major Manufacturing Expansion With $100 Million Investment In New England, Providing Global Capacity To Clients 5/11/2022

    PCI Pharma Services (PCI), a leading global contract development and manufacturing organization (CDMO), announced a major expansion of capabilities and capacity in aseptic liquid fill-finish and sterile lyophilization technology, an important manufacturing process commonly used with injectable and biologic therapies, with the investment of $100 million into the construction and enhancement of world-class facilities, at its Bedford, New Hampshire campus.

  3. Societal CDMO Signs Three-Year Manufacturing And Supply Agreement With InfectoPharm For Ritalin LA In Europe 5/5/2022

    Societal CDMO, Inc., a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today announced that it has entered into a three-year manufacturing and supply agreement with InfectoPharm for Ritalin LA capsules (methylphenidate hydrochloride extended-release capsules) in Europe.

  4. Societal CDMO Signs Three-Year Manufacturing And Supply Agreement With InfectoPharm For Ritalin LA® In Europe 5/5/2022

    Societal CDMO, Inc. (“Societal CDMO” or “Societal”; NASD: SCTL), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today announced that it has entered into a three-year manufacturing and supply agreement with InfectoPharm for Ritalin LA® capsules (methylphenidate hydrochloride extended-release capsules) in Europe

  5. Stevanato Group And Owen Mumford Sign Exclusive Collaboration Agreement For The Innovative Aidaptus® Auto-Injector 5/4/2022

    The Aidaptus® disposable auto-injector platform, designed by Owen Mumford, will be jointly offered to global biopharma companies to support their drug development programs with engineering and manufacturing support provided by Stevanato Group.

  6. Grand River Aseptic Manufacturing Invests $160M With Award From U.S. Government To Support Continued And Future Growth 4/28/2022

    Grand River Aseptic Manufacturing ("GRAM"), a leading parenteral contract development and manufacturing organization (CDMO), has signed a multi-year contract with the U.S. Department of Health and Human Services and the U.S. Department of Defense

  7. CDMO Grand River Aseptic Manufacturing To Invest $160 Into Manufacturing Expansion In Michigan 4/28/2022

    Grand River Aseptic Manufacturing (“GRAM”), a leading parenteral contract development and manufacturing organization (CDMO), has signed a multi-year contract with the U.S. Department of Health and Human Services and the U.S. Department of Defense.

  8. Virpax Pharmaceuticals Selects Kindeva Drug Delivery As Development Partner For Diclofenac pMDI Commercialization 4/27/2022

    Virpax Pharmaceuticals, Inc. (NASDAQ: VRPX) and Kindeva Drug Delivery will work together to advance the clinical program of the Virpax-developed Diclofenac topical spray film (Epoladerm™) in the United States.

  9. Mithra CDMO Announces Collaboration With MedinCell For The Development Of Injectable Products For Malaria And Transplant Rejection 4/26/2022

    Mithra today announced a collaboration with MedinCell for the development of two long-acting injectable products in its CDMO based in Liège

  10. Dutch CDMO BioConnection Announces Substantial Investment By Gimv, Supported By Existing Shareholders 4/22/2022

    BioConnection, an independent CDMO (Contract Development Manufacturing Organization) based in Oss, The Netherlands, specialized in GMP-certified manufacturing of sterile drug products in vials and syringes, today announced the completion of a new capital raising led by the European investment company Gimv, and supported by existing shareholders Pharming Group N.V., Mibiton and BioConnection's own management